[
  {
    "ts": null,
    "headline": "Guggenheim Reiterates a Buy Rating on AbbVie (ABBV), Sets a PT of $227",
    "summary": "AbbVie Inc. (NYSE:ABBV) is one of the best drug stocks to buy right now. In a report released on September 11, Vamil Divan from Guggenheim reiterated a Buy rating on AbbVie Inc. (NYSE:ABBV), setting a price target of $227.00. In its fiscal Q2 2025 results, AbbVie Inc. (NYSE:ABBV) reported a diluted EPS of $0.52 on a […]",
    "url": "https://finnhub.io/api/news?id=24e3c6d2f9989765283cc3c4ec765243daa682127bb0be3fef8f7a639269b604",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758052690,
      "headline": "Guggenheim Reiterates a Buy Rating on AbbVie (ABBV), Sets a PT of $227",
      "id": 136782163,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie Inc. (NYSE:ABBV) is one of the best drug stocks to buy right now. In a report released on September 11, Vamil Divan from Guggenheim reiterated a Buy rating on AbbVie Inc. (NYSE:ABBV), setting a price target of $227.00. In its fiscal Q2 2025 results, AbbVie Inc. (NYSE:ABBV) reported a diluted EPS of $0.52 on a […]",
      "url": "https://finnhub.io/api/news?id=24e3c6d2f9989765283cc3c4ec765243daa682127bb0be3fef8f7a639269b604"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: Best Time To Sell In 5 Years (Rating Downgrade)",
    "summary": "AbbVie Inc. is downgraded to sell amid valuation risks, low dividend yield, rising debt, and policy uncertainties. Click for our ABBV stock update.",
    "url": "https://finnhub.io/api/news?id=3024201016fd79d27ca30ad93b19190bcea45a2c2ae0c7cd186000811c124ce0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758038627,
      "headline": "AbbVie: Best Time To Sell In 5 Years (Rating Downgrade)",
      "id": 136782036,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2175801616/image_2175801616.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "AbbVie Inc. is downgraded to sell amid valuation risks, low dividend yield, rising debt, and policy uncertainties. Click for our ABBV stock update.",
      "url": "https://finnhub.io/api/news?id=3024201016fd79d27ca30ad93b19190bcea45a2c2ae0c7cd186000811c124ce0"
    }
  },
  {
    "ts": null,
    "headline": "Is ABBV Stock a Buy, Hold, or Sell After Its Almost 23% Rise YTD?",
    "summary": "AbbVie surges 22.5% YTD as new drugs Skyrizi and Rinvoq drive growth, offsetting Humira losses and fueling long-term momentum.",
    "url": "https://finnhub.io/api/news?id=00a8d4a15be08a625d7c1fccc39ccddfca8ab52f3d09047edb68cea629a8bb57",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758037860,
      "headline": "Is ABBV Stock a Buy, Hold, or Sell After Its Almost 23% Rise YTD?",
      "id": 136773222,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie surges 22.5% YTD as new drugs Skyrizi and Rinvoq drive growth, offsetting Humira losses and fueling long-term momentum.",
      "url": "https://finnhub.io/api/news?id=00a8d4a15be08a625d7c1fccc39ccddfca8ab52f3d09047edb68cea629a8bb57"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie (ABBV)’s Dividend Track Record: How It Became a Leader in Consistent Dividends",
    "summary": "AbbVie Inc. (NYSE:ABBV) is included among the 13 Best Consistent Dividend Stocks to Buy Now. AbbVie Inc. (NYSE:ABBV) is an Illinois-based pharmaceutical company. It has delivered strong results in 2025, easily beating the broader market. Much of this momentum comes from solid growth in sales and adjusted earnings, driven largely by its autoimmune treatments Rinvoq […]",
    "url": "https://finnhub.io/api/news?id=6c6c41e55ec36effcd5cd08364da35e492cfa9c128277d437066c904dd84dde8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758034452,
      "headline": "AbbVie (ABBV)’s Dividend Track Record: How It Became a Leader in Consistent Dividends",
      "id": 136773290,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie Inc. (NYSE:ABBV) is included among the 13 Best Consistent Dividend Stocks to Buy Now. AbbVie Inc. (NYSE:ABBV) is an Illinois-based pharmaceutical company. It has delivered strong results in 2025, easily beating the broader market. Much of this momentum comes from solid growth in sales and adjusted earnings, driven largely by its autoimmune treatments Rinvoq […]",
      "url": "https://finnhub.io/api/news?id=6c6c41e55ec36effcd5cd08364da35e492cfa9c128277d437066c904dd84dde8"
    }
  },
  {
    "ts": null,
    "headline": "Assessing AbbVie After Neuro Pipeline Expansion and Double Digit 2025 Share Gains",
    "summary": "If you have been watching AbbVie lately and wondering whether now is the right time to buy, sell, or simply hold on, you are definitely not alone. The stock has notched an impressive 21.3% gain year-to-date, powered in part by promising moves in its pipeline. Just this past month, AbbVie’s share price climbed 5.3%, while its one-year return currently stands at 15.2%. Those numbers are eye-catching, whether you are a long-term investor riding the nearly 200% five-year return or someone just...",
    "url": "https://finnhub.io/api/news?id=3882c680f123b4cfeb530d8ca900598e4dc3ed1bc69d281e06ba894a17f92c53",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758024280,
      "headline": "Assessing AbbVie After Neuro Pipeline Expansion and Double Digit 2025 Share Gains",
      "id": 136773291,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "If you have been watching AbbVie lately and wondering whether now is the right time to buy, sell, or simply hold on, you are definitely not alone. The stock has notched an impressive 21.3% gain year-to-date, powered in part by promising moves in its pipeline. Just this past month, AbbVie’s share price climbed 5.3%, while its one-year return currently stands at 15.2%. Those numbers are eye-catching, whether you are a long-term investor riding the nearly 200% five-year return or someone just...",
      "url": "https://finnhub.io/api/news?id=3882c680f123b4cfeb530d8ca900598e4dc3ed1bc69d281e06ba894a17f92c53"
    }
  }
]